Last reviewed · How we verify

NCT06834477

Impact of Structural and Microenvironmental Abnormalities in Olfactory Cleft on Olfaction in CRS

Not yet recruiting Last updated 19 February 2025
What this trial tests

trial testing Computed Tomography in Chronic Rhinosinusitis (CRS) in 80 participants. Not yet recruiting.

Timeline
14 March 2025
Primary endpoint
14 March 2027
14 March 2027

Quick facts

Lead sponsorPeking University Third Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment80
Start date14 March 2025
Primary completion14 March 2027
Estimated completion14 March 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 80, any sex, with Chronic Rhinosinusitis (CRS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to investigate the impact of structural abnormalities and microenvironmental changes in the olfactory cleft on olfactory function in patients with chronic rhinosinusitis (CRS). It sought to elucidate the complex relationships among structural abnormalities, microenvironmental changes, and inflammatory factors contributing to olfactory dysfunction through a multidimensional assessment encompassing imaging, aerodynamics, biomarker , and histopathology analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Computed Tomography

Trials testing the same drug.

Other recruiting trials for Chronic Rhinosinusitis (CRS)

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06834477.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing